PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Image Solutions, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ISI Reports 60 Percent Increase in Revenue in 2006 - A sixth straight year of double-digit growth. Company aggressively expanded professional staff and expanded facilities over the last year
ISI Reports 60 Percent Increase in Revenue in 2006


NewswireToday - /newswire/ - Whippany, NJ, United States, 2007/02/12 - A sixth straight year of double-digit growth. Company aggressively expanded professional staff and expanded facilities over the last year.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Image Solutions, Inc. (ISI), a global technology company and a proven leader in delivering software and services, reported a 60 percent increase in 2006 revenue over the same period in 2005 with strong profit and cash flow. ISI’s solutions support paper and electronic regulatory document submissions and clinical trials management in regions worldwide.

“Our sales performance this year was very strong and represents our most successful year in our 15 year history,” said ISI CEO and President, Jinsoo Kim. “Customer adoption of our technologies and service offerings has been extremely strong this year, and the flexibility of our global solution portfolio has enabled ISI to capture the accelerating market growth in the United States, Europe and Asia.”

ISI achieved dramatic revenue growth and an increase in the number of new clients. Most revenue was derived from ISI’s core competencies in electronic submission services, software license revenue and professional consulting.

Significant Achievements in 2006 Included:
Increased its core client base by more than 50 percent to a total of 120 clients, including the top 50 Pharmaceutical and Biotechnology organizations worldwide, as well as many mid-sized and emerging companies.

Expanded worldwide professional staff and facilities in 2006, increasing the number of employees and office facilities worldwide by almost 50 percent.

Hit major milestones in electronic submissions (eCTDs): 600 eSubmissions and more than 350 eCTD's

Launched a flexible regulatory solutions platform that leverages Microsoft .NET Framework and is based on reusable software objects that can quickly accommodate new standards and adapt to a variety of client environments and regulatory requirements.

Experienced a significant increase in the volume of large global projects, in addition to the number and diversity of projects for smaller to mid-size Pharmaceutical and Biotechnology organizations.

ISI’s CEO and President, Jinsoo Kim’s appointed as a finalist for Ernst & Young’s Entrepreneur of the Year (EOY) Award.

ISI’s sixth nomination to the Deloitte & Touché New Jersey Technology Fast 50 list.

“Growing demand for business process outsourcing and global solutions that improve workflow, speed regulatory review and improve drug manufacturer’s time-to-market continue to drive demand for ISI’s unique ability to blend software and services for process support solutions,” said Peter Kim, CFO and Vice President of Finance. “Many of our clients are seeing long-term productivity benefits by adopting ISI’s suite of solutions and services early in the drug development lifecycle, particularly for global implementations. Our solutions are designed to meet the unique needs of our global customers and the emerging standards being set by regulatory agencies worldwide.

“Further, with the tight integration of ISI’s flagship products, eCTDXPress, ISIPublisher and ISIRegTracker, along with our tools and templates, ISI can help facilitate submission document authoring, lifecycle management and publishing, while gaining greater acceptance among global pharmaceutical organizations seeking the efficiencies that can be realized through web-based enterprise collaboration and multi-region submissions,” continued Kim.

ISI has worked extremely hard over the past few years to broaden its solutions portfolio across the drug development continuum, incorporating into its solutions many of the complex requirements that clients require. “Having been strategic in our product development efforts and our professional services offerings has enhanced our already strong technology position within the Life Sciences industry, and will continue to advance ISI’s future expansion into new markets. Combined, the offerings represent a unique solution for any organization seeking to facilitate secure, compliant, enterprise-wide regulatory and clinical solutions,” added Paul Chung, Senior Vice President of Software and Service Operations at ISI.

ISI continued its practice of contributing 10 percent of net profit each year to charitable organizations like the United Way, Salvation Army, American Red Cross, UNICEF, Wishing Well Foundation, Habitat for Humanity, Compassion International, World Vision, Special Olympics – NJ, NJ Wheat Mission, Leukemia Society of America, Elizabeth Glaser Pediatric AIDS Foundation, Community Food Bank of New Jersey, Employment Horizons, Market Street Mission, Literacy Volunteers of Morris County and NJ Deaf Children’s Association.

CEO Jinsoo Kim summarized the company’s predicted growth in 2007, “ISI expects to see continued growth in pharmaceutical market share over the next year, and will continue to grow our best-in-class technology and solutions approach including the enhancement of its clinical solution suite to accommodate the industry’s current business processes and a move to Electronic Data Capture.”

About Image Solutions, Inc. (ISI)
Founded in 1992, Image Solutions, Inc. ( is a proven market leader in providing submissions solutions, process services and consulting to Life Science organizations as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firm to deliver electronic submissions to the industry and has since delivered more than 600 electronic submissions. ISI serves the top 50 Pharmaceutical and Biotech organizations, in addition to the top companies in other regulated industries.

ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the US, Europe and Asia. For more information, visit the company website.

Image Solutions, Inc., eCTDXPress, ISIPublisher and ISIRegTracker are trademarks or registered trademarks of Image Solutions, Inc. which may be registered in the United States and internationally. Other brand names may be trademarks or registered trademarks of others.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Image Solutions, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

ISI Reports 60 Percent Increase in Revenue in 2006

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Lisa Meyer - 
973-560-0404 lisa.meyer[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Image Solutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Image Solutions, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  RightITnow Ltd

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (